Capricor Therapeutics Q1 2024 GAAP EPS $(0.31) Misses $(0.11) Estimate, Sales $4.906M Miss $9.700M Estimate
Portfolio Pulse from Benzinga Newsdesk
Capricor Therapeutics (NASDAQ:CAPR) reported Q1 2024 GAAP EPS of $(0.31), missing the $(0.11) estimate, and sales of $4.906M, missing the $9.700M estimate. Despite these misses, sales increased 64.25% from the same period last year.
May 13, 2024 | 8:16 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Capricor Therapeutics reported a significant miss in both EPS and sales for Q1 2024, with EPS at $(0.31) against an $(0.11) estimate and sales of $4.906M against a $9.700M estimate. However, sales showed a notable increase of 64.25% compared to the same period last year.
The significant miss in both EPS and sales estimates is likely to negatively impact investor sentiment and the stock price in the short term. However, the substantial year-over-year sales growth may provide some offsetting positive sentiment.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100